Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evaluating Selinexor and
View HTML
Toggle Summary Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award
-- Dr. Shacham Recognized for Research That Led to the Development of Oral Selinexor and other SINE Compounds -- NEWTON, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief
View HTML
Toggle Summary Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
--  FDA Extends Review Period for Selinexor New Drug Application to July 6 , 2019 -- -- Selinexor MAA Validated in Europe ; Approval Decision Expected by End of 2019 -- -- Conference Call Scheduled for Today at 8:30 a.m. ET -- NEWTON, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics
View HTML
Toggle Summary Karyopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Bank of America Merrill Lynch Health Care
View HTML
Toggle Summary Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019
-- Conference Call Scheduled for Thursday, May 9, 2019 at 8:30 a.m. ET -- NEWTON, Mass. , May 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2019 financial results on Thursday, May
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 89,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 38,000 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
- PDUFA Action Date Extended by Three Months to July 6, 2019 - - FDA Has Requested Additional Existing Information for Review - NEWTON, Mass. , March 14, 2019 /PRNewswire/ --  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S.
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that it has granted stock options to Michael P. Mason , the Company’s newly-appointed Senior Vice President, Chief Financial Officer and Treasurer,
View HTML
Toggle Summary Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
--  FDA Advisory Committee Votes 8 to 5 Recommending FDA Wait for the Results from the Ongoing Phase 3 BOSTON Study to Make an Approval Decision for Selinexor -- -- Company Working with FDA to Evaluate Best Path Forward as FDA Completes Its Review of Selinexor NDA; Assigned PDUFA Action Date of
View HTML